Taysha Gene Therapies Introduces New Employee Inducement Grants
Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a prominent clinical-stage biotechnology company, is dedicated to revolutionizing treatments for severe monogenic diseases of the central nervous system (CNS). Recently, Taysha's Compensation Committee took a significant step forward by granting stock options to incentivize new talent during their strategic expansion.
Details of the Stock Options
On a recent date that focused on enhancing team dynamics, two new employees received the opportunity to acquire an impressive number of stock options. Specifically, they were granted options to purchase 30,000 shares of Taysha's common stock. This generous offering demonstrates Taysha's commitment to attracting talented individuals passionate about gene therapy and innovation.
The stock options come with an exercise price that mirrors the closing stock price of Taysha's shares on the grant date. Each option carries a 10-year lifespan and will be vested over a total of four years. The initial 25% will vest on the first anniversary, followed by the remaining 75% vesting in equal monthly portions over the next 36 months, contingent upon the employees' ongoing service to the company.
About Taysha Gene Therapies
Taysha Gene Therapies stands out in the biotechnology sector for its unwavering focus on advancing adeno-associated virus (AAV)-based gene therapies. Their primary clinical initiative, designated as TSHA-102, is targeted toward treating Rett syndrome, a rare neurodevelopmental disorder with significantly unmet medical needs. This condition has no currently approved therapies addressing its genetic origins.
With a steadfast mission to develop transformative medicines, Taysha's team is committed to improving the lives of patients and their families. The experience possessed by the management team is instrumental, leveraging their proven track record in gene therapy research and commercialization. By utilizing a clinically validated manufacturing process and an AAV9 capsid, Taysha excels at hastening the transition of therapies from research to real-world applications.
Contact Information for Inquiries
For further information about Taysha Gene Therapies or its initiatives, interested parties can reach out to:
Hayleigh Collins
Senior Director of Corporate Communications and Investor Relations
Taysha Gene Therapies, Inc.
Email: hcollins@tayshagtx.com
Frequently Asked Questions
What is the purpose of the stock options granted by Taysha?
The stock options are aimed at incentivizing and rewarding new employees for their contributions to Taysha's mission in advancing gene therapies.
How does Taysha's stock option vesting schedule work?
The stock options vest over four years, with an initial 25% vesting on the first anniversary and the remaining 75% distributed monthly over the following 36 months.
What is Taysha's leading clinical program?
Taysha's leading program, TSHA-102, is in development for treating Rett syndrome, a rare neurodevelopmental disorder.
What is Taysha's approach to gene therapy?
Taysha focuses on using adeno-associated virus (AAV)-based gene therapies to address severe monogenic diseases, aiming for transformative solutions in patient care.
How can I contact Taysha for more information?
Inquiries can be directed to Hayleigh Collins, Senior Director, Corporate Communications and Investor Relations at hcollins@tayshagtx.com.
